Walleye Capital LLC Sells 154,940 Shares of Personalis, Inc. (NASDAQ:PSNL)

Walleye Capital LLC lessened its stake in shares of Personalis, Inc. (NASDAQ:PSNL) by 92.9% in the 4th quarter, HoldingsChannel.com reports. The fund owned 11,848 shares of the company’s stock after selling 154,940 shares during the period. Walleye Capital LLC’s holdings in Personalis were worth $68,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of PSNL. abrdn plc bought a new stake in shares of Personalis during the fourth quarter valued at approximately $1,722,000. Jane Street Group LLC raised its stake in Personalis by 154.3% in the third quarter. Jane Street Group LLC now owns 164,281 shares of the company’s stock worth $884,000 after buying an additional 99,671 shares in the last quarter. Geode Capital Management LLC raised its stake in Personalis by 20.0% in the third quarter. Geode Capital Management LLC now owns 498,470 shares of the company’s stock worth $2,683,000 after buying an additional 83,068 shares in the last quarter. EntryPoint Capital LLC bought a new position in Personalis in the fourth quarter worth approximately $275,000. Finally, State Street Corp raised its stake in Personalis by 34.5% in the third quarter. State Street Corp now owns 175,142 shares of the company’s stock worth $942,000 after buying an additional 44,900 shares in the last quarter. Institutional investors own 61.91% of the company’s stock.

Wall Street Analysts Forecast Growth

PSNL has been the subject of a number of recent research reports. Lake Street Capital boosted their price objective on shares of Personalis from $7.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of Personalis in a research note on Friday, February 28th. Needham & Company LLC reissued a “buy” rating and issued a $7.00 price objective on shares of Personalis in a research note on Thursday, April 10th. Finally, Craig Hallum initiated coverage on Personalis in a research report on Monday, March 17th. They set a “buy” rating and a $8.00 price target on the stock. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $7.80.

Personalis Trading Up 0.3 %

Shares of PSNL stock opened at $3.84 on Monday. The business’s fifty day simple moving average is $3.73 and its 200-day simple moving average is $4.49. The company has a market cap of $339.10 million, a PE ratio of -2.29 and a beta of 1.89. Personalis, Inc. has a 12-month low of $1.14 and a 12-month high of $7.20.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.09. The business had revenue of $16.80 million for the quarter, compared to the consensus estimate of $15.48 million. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. On average, equities analysts forecast that Personalis, Inc. will post -1.4 earnings per share for the current year.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.